Literature DB >> 8641028

Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries.

N Singh1, D Mironov, P W Armstrong, A M Ross, A Langer.   

Abstract

BACKGROUND: Diminished heart rate variability is associated with less favorable prognosis after myocardial infarction. However, the prognostic value of early (first 48 hours) measurement and the influence of thrombolytic strategies, myocardial infarction location, left ventricular function, ST-segment shift, and infarct-related artery patency on heart rate variability have not been examined comprehensively. METHODS AND
RESULTS: Heart rate variability and ST-segment analysis of 48-hour Holter tapes were performed with the use of a commercial system in 204 patients who were part of an ST-monitoring substudy of the Global Utilization of Streptokinase and TPA for Occluded Arteries (GUSTO-I) trial. Both time-domain measures (SD of the average normal RR interval for all 5-minute segments of a 24-hour ECG recording [SDANN] and percent difference between adjacent normal RR intervals > 50 ms computed over the entire 24-hour ECG recording [pNN50]) and frequency-domain measures (low frequency [LF], high frequency [HF], and LF/HF ratio) were assessed on days 1 and 2 after acute myocardial infarction. Coronary angiography performed within the first 24 hours was also available in 75% of the patients. All heart rate variability measures decreased between day 1 and day 2 (P = .001) except the LF/HF ratio. There was no difference in heart rate variability among groups assigned to one of four different thrombolytic treatment strategies (streptokinase/subcutaneous heparin, streptokinase/intravenous heparin, accelerated tissue plasminogen activator, and combination streptokinase/tissue plasminogen activator). Heart rate variability measures were lower in anterior versus nonanterior infarcts (SDANN, 53 +/- 21 versus 63 +/- 24 ms; P < .005) and increased with TIMI grade 3 flow (LF, 5.3 +/- 1.0 versus 4.8 +/- 1.2 ms2; P < .01) and better ejection fraction (r = .2, P < .03). An inverse correlation between the duration of ST shift and frequency domain measures was observed (LF, r = -.2, P < .009; HF, r = -2, P < .03). Lower LF/HF ratio by 24 hours after myocardial infarction was seen in those who ultimately died at 30 days (1.0 +/- 0.2 versus 1.3 +/- 0.2, P < .001) or at 1 year (1.17 +/- 0.14 versus 1.26 +/- 0.19, P = .05).
CONCLUSIONS: Changes in heart rate variability occurred early after thrombolysis and may be of prognostic value. Heart rate variability measures were improved in patients with better ejection fraction and greater angiographic patency. This suggests a possible mechanism for the enhanced survival observed with TIMI grade 3 flow in the GUSTO angiographic substudy. These data indicate that early heart rate variability assessment after myocardial infarction may be useful in noninvasive risk stratification.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641028     DOI: 10.1161/01.cir.93.7.1388

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

1.  Increased cardiac sympathetic nerve activity following acute myocardial infarction in a sheep model.

Authors:  D L Jardine; C J Charles; R K Ashton; S I Bennett; M Whitehead; C M Frampton; M G Nicholls
Journal:  J Physiol       Date:  2005-03-17       Impact factor: 5.182

Review 2.  Electrocardiographic predictors of arrhythmic death.

Authors:  Michael G McLaughlin; Peter J Zimetbaum
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-10       Impact factor: 1.468

3.  Do the deceleration/acceleration capacities of heart rate reflect cardiac sympathetic or vagal activity? A model study.

Authors:  Qing Pan; Gongzhan Zhou; Ruofan Wang; Guolong Cai; Jing Yan; Luping Fang; Gangmin Ning
Journal:  Med Biol Eng Comput       Date:  2016-04-08       Impact factor: 2.602

4.  QT dispersion as a predictor for arrhythmias in patients with acute ST elevation myocardial infarction.

Authors:  Fahad Aziz; Sujatha Doddi; Anshu Alok; Sudheer Penupolu; Vijayant Singh; Michael Benz; Mary Abed
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

5.  Prognostic value of ventricular arrhythmias and heart rate variability in patients with unstable angina.

Authors:  G A Lanza; D Cianflone; A G Rebuzzi; G Angeloni; A Sestito; G Ciriello; G La Torre; F Crea; A Maseri
Journal:  Heart       Date:  2005-12-30       Impact factor: 5.994

6.  Electrophysiological effects of late percutaneous coronary intervention for infarct-related coronary artery occlusion: the Occluded Artery Trial-Electrophysiological Mechanisms (OAT-EP).

Authors:  Eric J Rashba; Gervasio A Lamas; Jean-Philippe Couderc; Sharri M Hollist; Vladimir Dzavik; Witold Ruzyllo; Viliam Fridrich; Christopher E Buller; Sandra A Forman; Joseph A Kufera; Antonio C Carvalho; Judith S Hochman
Journal:  Circulation       Date:  2009-02-02       Impact factor: 29.690

7.  Prognostic value of heart rate variability after acute myocardial infarction in the era of immediate reperfusion.

Authors:  Ali Erdogan; Michael Coch; Mehmet Bilgin; Mariana Parahuleva; Harald Tillmanns; Bernd Waldecker; Nedim Soydan
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2009-02-11

8.  Depressive symptoms and heart rate variability: evidence for a shared genetic substrate in a study of twins.

Authors:  Viola Vaccarino; Rachel Lampert; J Douglas Bremner; Forrester Lee; Shaoyong Su; Carisa Maisano; Nancy V Murrah; Linda Jones; Farhan Jawed; Nadeem Afzal; Ali Ashraf; Jack Goldberg
Journal:  Psychosom Med       Date:  2008-07       Impact factor: 4.312

Review 9.  Complex systems and the technology of variability analysis.

Authors:  Andrew J E Seely; Peter T Macklem
Journal:  Crit Care       Date:  2004-09-22       Impact factor: 9.097

10.  Effect of Omacor on HRV parameters in patients with recent uncomplicated myocardial infarction - A randomized, parallel group, double-blind, placebo-controlled trial: study design [ISRCTN75358739].

Authors:  Cornel Pater; Daniele Compagnone; Joachim Luszick; Cees-Nico Verboom
Journal:  Curr Control Trials Cardiovasc Med       Date:  2003-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.